Phelan Mcdermid Syndrome Foundation is ranked among medical research organizations in Osprey, FL, with an America's Best Score of 83 out of 100, based on its 2025 Form 990.
The mission of the Phelan-McDermid Syndrome Foundation is to make today better and the future brighter for everyone living with Phelan-McDermid syndrome - from the moment of diagnosis to the delivery of treatments and cures.
Largest programs · fiscal year 2025
CONNECT (Family Support): The Organization (PMSF) connects with families from diagnosis throughout their life journey, providing essential support, knowledge, and skills to navigate the complexities of Phelan Mc-Dermid syndrome. In 2025, PMSF provided 2,400 connections through comprehensive support services, welcoming 300 new families into membership. Key initiatives included supporting 133 newly… Read more
CONNECT (Family Support): The Organization (PMSF) connects with families from diagnosis throughout their life journey, providing essential support, knowledge, and skills to navigate the complexities of Phelan Mc-Dermid syndrome. In 2025, PMSF provided 2,400 connections through comprehensive support services, welcoming 300 new families into membership. Key initiatives included supporting 133 newly diagnosed families via the "First 100 Days" program, educating 250 caregivers and professionals through the "Pathways" video series, and facilitating 48 Caregiver Support Group sessions for 250 participants. These programs integrate mental health, social, and emotional well-being, while regional and international gatherings further empower our community to thrive.
$192,052 spent · 27.1% of program spending
CARE (Improving Medical Care): The Organization (PMSF) ensures that individuals with Phelan-McDermid syndrome have access to a robust community of specialists and evidence-based care. We bridge the gap between research and clinical practice by educating professionals, facilitating medical consultation, and expanding our specialized clinical infrastructure. In 2025, we strengthened this ecosystem b… Read more
CARE (Improving Medical Care): The Organization (PMSF) ensures that individuals with Phelan-McDermid syndrome have access to a robust community of specialists and evidence-based care. We bridge the gap between research and clinical practice by educating professionals, facilitating medical consultation, and expanding our specialized clinical infrastructure. In 2025, we strengthened this ecosystem by establishing our first 11 Phelan-McDermid Syndrome Clinics-including a new multidisciplinary center at Cincinnati Children's Hospital Medical Center-and launched initiatives to grow our Healthcare Provider (HCP) network. Our experts facilitated 22 neuropsychiatric consultation cases, 15 neuropsychiatric referrals, and 50 genetic counseling referrals. Additionally, we served as a primary medical hub, recording over 100,000 views on pmsf.org and overseeing 3,500 downloads of clinical and educational resource documents.
$168,860 spent · 23.8% of program spending
CURE (Driving Research Breakthroughs): The Organization (PMSF) accelerates scientific discovery by centering the patient experience in research, expanding our clinical data infrastructure, and providing critical funding. In 2025, our grant committee awarded the Shannon O'Boyle Memorial Grant to Dr. Jonathan Santoro (Children's Hospital of Los Angeles) to advance vital neuropsychiatric biomarker re… Read more
CURE (Driving Research Breakthroughs): The Organization (PMSF) accelerates scientific discovery by centering the patient experience in research, expanding our clinical data infrastructure, and providing critical funding. In 2025, our grant committee awarded the Shannon O'Boyle Memorial Grant to Dr. Jonathan Santoro (Children's Hospital of Los Angeles) to advance vital neuropsychiatric biomarker research. We expanded the PMSF DataHub to 1,500 consented participants and 1,400 curated genetic reports, creating an invaluable resource for pharmaceutical and clinical partners. Furthermore, we directly facilitated participation in the Developmental Synaptopathies Consortium natural history study by providing travel reimbursements to 24 families. Our commitment to global knowledge-sharing was underscored by the PMSF podcast, which experienced 500% growth and reached audiences in 30 countries.
$348,155 spent · 49.1% of program spending
Where each dollar went · fiscal year 2025
Of every dollar it spent, 66¢ went to programs, 16¢ to management and 18¢ to fundraising.
Programs $709,067
Management $174,572
Fundraising $198,735
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
66%
Meets
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$1,245,861Fiscal year 2025
Expenses$1,082,374Fiscal year 2025
Total assets$2,220,653Fiscal year 2025
Total liabilities$154,468Fiscal year 2025
Fiscal year ending December2025
Revenue$1,245,861
Expenses$1,082,374
Net income$163,487
Net assets$2,066,185
Notable sources of revenue
Percent of total revenue
Contributions
$1,060,585
85.1%
Program services
$14,143
1.1%
Investment income
$96,976
7.8%
Other (net)
$74,157
6.0%
Assets / debt
Total assets
$2,220,653
Total liabilities
$154,468
Net assets
$2,066,185
Compensation
Not in our extract for this year.
Fiscal year ending December2024
Revenue$1,306,884
Expenses$1,437,564
Net income−$130,680
Net assets$1,899,342
Notable sources of revenue
Percent of total revenue
Contributions
$1,084,905
83.0%
Program services
$67,727
5.2%
Investment income
$44,888
3.4%
Other (net)
$109,364
8.4%
Assets / debt
Total assets
$2,109,869
Total liabilities
$210,527
Net assets
$1,899,342
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$1,062,761
Expenses$1,098,819
Net income−$36,058
Net assets$2,026,828
Notable sources of revenue
Percent of total revenue
Contributions
$834,914
78.6%
Program services
$110,073
10.4%
Investment income
$14,095
1.3%
Other (net)
$103,679
9.8%
Assets / debt
Total assets
$2,243,009
Total liabilities
$216,181
Net assets
$2,026,828
Compensation
Not in our extract for this year.
Fiscal year ending December2022
Revenue$853,648
Expenses$715,263
Net income$138,385
Net assets$2,054,440
Notable sources of revenue
Percent of total revenue
Contributions
$744,192
87.2%
Program services
$34,615
4.1%
Investment income
−$8,775
−1.0%
Other (net)
$83,616
9.8%
Assets / debt
Total assets
$2,113,920
Total liabilities
$59,480
Net assets
$2,054,440
Compensation
Officers and key employees
$108,000
Share of expenses
15.1%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?